• Je něco špatně v tomto záznamu ?

[18 F]Fluorodeoxyglucose PET/CT and prediction of histopathological response to neoadjuvant chemotherapy for adenocarcinoma of the oesophagus and oesophagogastric junction

T. Harustiak, M. Zemanova, P. Fencl, L. Hornofova, A. Pazdro, M. Snajdauf, E. Salkova, R. Lischke, A. Stolz,

. 2018 ; 105 (4) : 419-428. [pub] 20180208

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc19000930

BACKGROUND: The aim of this prospective study was to assess whether [18 F]fluorodeoxyglucose PET can be used to predict histopathological response early in the course of neoadjuvant chemotherapy in patients with adenocarcinoma of the oesophagus and oesophagogastric junction. METHODS: Following the PET response criteria in solid tumours (PERCIST 1.0) as a standardized method for semiquantitative assessment of metabolic response, FDG-PET/CT was performed before (PET1) and after (PET2) initiation of the first cycle of chemotherapy. The relative changes in the peak standardized uptake value (ΔSUL) and total lesion glycolysis (ΔTLG) between PET1 and PET2 were correlated with histopathological response, defined as less than 50 per cent viable tumour cells in the resection specimen. A receiver operating characteristic (ROC) curve analysis was used to identify the optimal cut-off value with the highest accuracy of histopathological response prediction. RESULTS: PET2 was performed a median of 16 (range 12-22) days after the start of chemotherapy. Some 27 of 90 patients who underwent surgery had a histopathological response. There was no association between the median ΔSUL or median ΔTLG and the histopathological response. A post hoc analysis in 47 patients with PET2 performed 16 days or less after the start of chemotherapy showed that ΔTLG, but not ΔSUL, was associated with the histopathological response (P = 0·009). The optimal cut-off value of ΔTLG was 66 per cent or more. CONCLUSION: FDG-PET/CT after the first cycle of chemotherapy does not predict histopathological response in patients with adenocarcinoma of the oesophagus and oesophagogastric junction.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19000930
003      
CZ-PrNML
005      
20190121110603.0
007      
ta
008      
190107s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/bjs.10712 $2 doi
035    __
$a (PubMed)29417984
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Harustiak, T $u Third Department of Surgery, First Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
245    10
$a [18 F]Fluorodeoxyglucose PET/CT and prediction of histopathological response to neoadjuvant chemotherapy for adenocarcinoma of the oesophagus and oesophagogastric junction / $c T. Harustiak, M. Zemanova, P. Fencl, L. Hornofova, A. Pazdro, M. Snajdauf, E. Salkova, R. Lischke, A. Stolz,
520    9_
$a BACKGROUND: The aim of this prospective study was to assess whether [18 F]fluorodeoxyglucose PET can be used to predict histopathological response early in the course of neoadjuvant chemotherapy in patients with adenocarcinoma of the oesophagus and oesophagogastric junction. METHODS: Following the PET response criteria in solid tumours (PERCIST 1.0) as a standardized method for semiquantitative assessment of metabolic response, FDG-PET/CT was performed before (PET1) and after (PET2) initiation of the first cycle of chemotherapy. The relative changes in the peak standardized uptake value (ΔSUL) and total lesion glycolysis (ΔTLG) between PET1 and PET2 were correlated with histopathological response, defined as less than 50 per cent viable tumour cells in the resection specimen. A receiver operating characteristic (ROC) curve analysis was used to identify the optimal cut-off value with the highest accuracy of histopathological response prediction. RESULTS: PET2 was performed a median of 16 (range 12-22) days after the start of chemotherapy. Some 27 of 90 patients who underwent surgery had a histopathological response. There was no association between the median ΔSUL or median ΔTLG and the histopathological response. A post hoc analysis in 47 patients with PET2 performed 16 days or less after the start of chemotherapy showed that ΔTLG, but not ΔSUL, was associated with the histopathological response (P = 0·009). The optimal cut-off value of ΔTLG was 66 per cent or more. CONCLUSION: FDG-PET/CT after the first cycle of chemotherapy does not predict histopathological response in patients with adenocarcinoma of the oesophagus and oesophagogastric junction.
650    _2
$a adenokarcinom $x diagnostické zobrazování $x farmakoterapie $x patologie $x chirurgie $7 D000230
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a antitumorózní látky $x terapeutické užití $7 D000970
650    _2
$a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a adjuvantní chemoterapie $7 D017024
650    _2
$a nádory jícnu $x diagnostické zobrazování $x farmakoterapie $x patologie $x chirurgie $7 D004938
650    _2
$a gastroezofageální junkce $x diagnostické zobrazování $x patologie $7 D004943
650    _2
$a ženské pohlaví $7 D005260
650    12
$a fluorodeoxyglukosa F18 $7 D019788
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a neoadjuvantní terapie $7 D020360
650    12
$a PET/CT $7 D000072078
650    _2
$a prospektivní studie $7 D011446
650    _2
$a ROC křivka $7 D012372
650    12
$a radiofarmaka $7 D019275
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Zemanova, M $u Department of Oncology, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic.
700    1_
$a Fencl, P $u Department of Nuclear Medicine and PET Centre, Na Homolce Hospital, Prague, Czech Republic.
700    1_
$a Hornofova, L $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Pazdro, A $u Third Department of Surgery, First Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Snajdauf, M $u Third Department of Surgery, First Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Salkova, E $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Lischke, R $u Third Department of Surgery, First Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Stolz, A $u Third Department of Surgery, First Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
773    0_
$w MED00009388 $t The British journal of surgery $x 1365-2168 $g Roč. 105, č. 4 (2018), s. 419-428
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29417984 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190121110821 $b ABA008
999    __
$a ok $b bmc $g 1364900 $s 1039053
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 105 $c 4 $d 419-428 $e 20180208 $i 1365-2168 $m British journal of surgery $n Br J Surg $x MED00009388
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Možnosti archivace